Insights into Profound Medical's Upcoming Financial Results
Profound Medical Announces Financial Results Release Date
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a notable player in the medical device field, is gearing up to unveil its fourth quarter and full year results for 2024. The announcement will take place after market close on an upcoming Thursday. This presentation is highly anticipated as it showcases the company's performance and strategic direction.
Conference Call to Discuss Financial Results
The management team at Profound Medical will follow the earnings announcement with a conference call scheduled for 4:30 p.m. ET. They will walk through the financial results and share insights into key business developments during the reporting period. Such calls are essential for investors and stakeholders to understand the company's trajectory and growth potential.
About Profound Medical Corp.
Profound Medical is on the cutting edge of medical technology, focusing on customizable and incision-free treatments for diseased tissue. Their flagship technology, TULSA-PRO, integrates advanced real-time MRI capabilities with ultrasound technology. This combination allows for precision treatment of various prostate conditions, positioning TULSA-PRO as a potential standard in prostate disease treatment.
Innovative Treatments with TULSA-PRO
The TULSA-PRO system employs robotically-driven transurethral ultrasound combined with closed-loop temperature feedback to deliver effective results. This innovative procedure is distinguished by its ability to preserve urinary continence and sexual function, while effectively targeting and destroying diseased tissue through the application of focused ultrasound energy. Patients undergoing TULSA experience a quick recovery without the need for hospitalization, thanks to the non-invasive nature of the procedure.
Profound's Additional Therapeutic Platforms
In addition to TULSA-PRO, Profound Medical is also pioneering the Sonalleve system, which is designed to treat uterine fibroids and provide palliative care for bone metastases. This technology has received CE marking and various regulatory approvals, including from the FDA and China's medical administration. The company is actively pursuing further applications for Sonalleve in treating cancers and hyperthermia therapy, underscoring their dedication to expanding their therapeutic portfolio.
Commitment to Innovation in Healthcare
Profound Medical's commitment to innovation is evident in its strategic approach to expanding its therapeutic solutions. Through rigorous research and development, the company is exploring additional markets that could benefit from their unique technologies, continuing to improve patient outcomes in the field of medical treatment.
Contact Information
For more details or inquiries related to investor relations, Stephen Kilmer can be reached via email or telephone. Stephen is an essential point of contact for those looking to gain further insights into the company’s plans and financial health.
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Frequently Asked Questions
When will Profound Medical's financial results be announced?
Profound Medical will announce its financial results on an upcoming Thursday after the market closes.
What is TULSA-PRO used for?
TULSA-PRO is used for the ablation of prostate tissue, providing incision-free options for various prostate diseases.
How does Profound Medical ensure patient safety?
Profound Medical's technologies are designed with precision guidance, minimizing risks and ensuring quick recovery without hospitalization.
What additional markets is Profound exploring for Sonalleve?
Profound Medical is exploring non-invasive treatments for a variety of abdominal cancers and hyperthermia therapy with Sonalleve.
Who can I contact for investor relations at Profound Medical?
For investor relations inquiries, you can contact Stephen Kilmer via email at skilmer@profoundmedical.com or by phone at 647.872.4849.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
